Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement

Mar

20

Today In Oncology

AMA Survey Finds Rapid Growth in Physician AI Adoption

For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit

High Cancer Burden Shifted From Urban to Rural Areas

Study Finds No Overall Increase in Cancer Risk After Medically Assisted Reproduction

SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy

Advertisement

© 2026 HSP News Service, L.L.C.